- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06203327
Atrophic Gastritis Predicts the Risk of Gastric Cancer
January 13, 2024 updated by: Hong Lu, MD, Shanghai Jiao Tong University School of Medicine
Atrophic Gastritis Predicts the Risk of Gastric Cancer: a Prospective Cohort Study
Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia.
The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC.
Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma.
The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC.
The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
2042
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Recruiting
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University
-
Principal Investigator:
- Hong Lu, M.D.,Ph.D
-
Sub-Investigator:
- Xiao Liang, M.D.,Ph.D
-
Contact:
- Yu Huang, M.M.
- Phone Number: 86+18621791879
- Email: 15626211482@163.com
-
Sub-Investigator:
- Jinnan Chen, M.M.
-
Sub-Investigator:
- Yixian Guo, M.M.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Chronic gastritis diagnosed by routine endoscopic screening
Description
Inclusion Criteria:
- Ability and willingness to participate in the study and to sign and give informed consent
- Biopsies were collected based on the recommendation of updated Sydney system
Exclusion Criteria:
- under 18 or over 80 years old
- history of gastrectomy
- severe systemic diseases or malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
OLGA 0-I
|
Surveillance endoscopies at years 3-5.
|
OLGA II
|
Surveillance endoscopies at years 2-3.
|
OLGA III-IV
|
Surveillance endoscopies every year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
early gastric neoplasm
Time Frame: After the baseline endoscopy, participants were scheduled for surveillance endoscopies at years 3-5 for subjects with operative link on gastritis assessment (OLGA) 0-Ⅰ, at years 2-3 for subjects with OLGA II and 1 year for subjects with OLGA III-IV.
|
histological diagnosis of high-grade dysplasia, and adenocarcinoma.
|
After the baseline endoscopy, participants were scheduled for surveillance endoscopies at years 3-5 for subjects with operative link on gastritis assessment (OLGA) 0-Ⅰ, at years 2-3 for subjects with OLGA II and 1 year for subjects with OLGA III-IV.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2024
Primary Completion (Estimated)
December 31, 2034
Study Completion (Estimated)
December 31, 2034
Study Registration Dates
First Submitted
December 25, 2023
First Submitted That Met QC Criteria
January 11, 2024
First Posted (Actual)
January 12, 2024
Study Record Updates
Last Update Posted (Estimated)
January 17, 2024
Last Update Submitted That Met QC Criteria
January 13, 2024
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- rjhy20230004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrophic Gastritis
-
Peking University First HospitalRecruitingChronic Atrophic GastritisChina
-
Xinjiang Biochemical Pharmaceutical Co., Ltd.CompletedChronic Atrophic Gastritis (CAG)China
-
Instituto Ecuatoriano de Enfermedades DigestivasCompletedAtrophic GastritisEcuador
-
Beijing University of Chinese MedicineHarvard Medical School (HMS and HSDM); China Academy of Chinese Medical Sciences and other collaboratorsRecruitingRisk Assessment of Chronic Atrophic Gastritis Malignant TransformationChina
-
Chinese University of Hong KongRecruitingAtrophic GastritisHong Kong
-
Beijing University of Chinese MedicineRecruitingChronic Atrophic GastritisChina
-
Wangjing Hospital, China Academy of Chinese Medical...Guangdong Provincial Hospital of Traditional Chinese Medicine; Xiyuan Hospital... and other collaboratorsCompletedChronic Atrophic GastritisChina
-
Beijing University of Chinese MedicineHarvard Medical School (HMS and HSDM); China Academy of Chinese Medical Sciences and other collaboratorsUnknownTCM Syndrome of Chronic Atrophic GastritisChina
-
National Cancer Institute (NCI)Active, not recruitingChronic Atrophic GastritisPuerto Rico, Honduras
-
Instituto Ecuatoriano de Enfermedades DigestivasCompletedGastritis | Atrophic Gastritis | Helicobacter Pylori Associated GastritisEcuador